Abstract This report brings the first experimental evidence for the presence of long-term (LT) repopulating hematopoietic stem cells (HSCs) and Side Population (SP) cells within human steady state peripheral blood CD34 + cells. Ex vivo culture, which reveals the LT-HSC, also increases short-term (ST) HSC engraftment capacity and SP cell number (as well as the SP subpopulations defined on the basis of CD38, CD90 and CD133 expression) which are very low in freshly isolated cells. Thus, ex vivo incubation either allows the expansion of the small fraction of HSCs or reveals "Scid Repopulating Cells -SRC" that are present in the initial CD34 + cell population but unable to engraft. In addition, among these CD34 + cells, we confirm the presence of committed progenitors at frequencies similar to those found in cord blood CD34 + cells. These cells, obtained from leukoreduction filters (LRFs) and rejected in the course of the preparation of red blood cell concentrates, are an abundant and reliable material for obtaining committed progenitors, short-and long-term HSCs of therapeutic interest, especially after the ex vivo expansion phase. Our results open a perspective to set up new therapeutic protocols using expanded LRFs-recovered CD34 + cells as a source of HSCs for autologous or allogeneic transplantation.
Introduction
The existence of circulating hematopoietic stem cells (HSCs) in steady state was suggested by the early experiments of parabiosis in rats (Brecher and Cronkite, 1951) and baboons (Storb et al., 1977) . These observations have been corroborated by hematopoietic reconstitution of irradiated animals via injection of steady state peripheral blood cells (Goodman and Hodgson, 1962; Cavins et al., 1964; Storb et al., 1968; Kőrbling et al., 1979) . Although several clinical studies in the 80s demonstrated a beneficial effect of autologous (Kőrbling et al., 1986; Reiffers et al., 1986) and allogeneic (Kessinger et al., 1989 ) peripheral blood cell transplantation, the presence of HSC in human steady state blood was not confirmed by specific experiments. However, the presence of committed and multi-lineage progenitors in steady state peripheral blood has been established both in the animal models and in humans (McCredie et al., 1971; Chervenick and Boggs, 1971; Barr et al., 1975; Ivanovic et al., 1997, Ivanovic and Milenkovic, 1999) , and these cells have been identified as belonging to the CD34 + population, whose frequency is very low in steady state blood (1 to 4 cells/μl) (Bender et al., 1991) . Surprisingly, after a phenomenon called "mobilization" i.e. increase in the number of committed progenitor cells in blood after chemotherapy (Richman et al., 1976) and cytokine treatment (GM-SCF or G-CSF) (Siena et al., 1990) , had been discovered, the studies on steady state peripheral blood cells were almost abandoned. Nevertheless, a couple of studies was published demonstrating the presence of HSC in blood using ex vivo LTC-IC (Long Term Culture Initiation Cells) (Udomsakdi et al., 1992) approach and in vivo (SRC; Scid Repopulating Cells) (Hirayama et al., 2003) approach. Nowadays, it is considered that the in vivo approach, based on the repopulation of hematopoietic tissues of immunodeficient mice, enables estimation of the real HSC capacity. Furthermore, depending on the approach -analysis of recipient mice several weeks after injection of human cells, or their bone marrow cell collection and injection to the secondary recipients which will be analyzed several weeks afterwards -it is possible to get insight into two populations of the heterogeneous HSC compartment: the short-(ST) and long-term (LT) repopulating hematopoietic stem cells, respectively (reviewed in: Ema, 2010) . Importantly, the approach using secondary recipients is now regarded as a "gold standard" to reveal the LT-HSC. The present study used described "gold standard" approach, as well as a complex phenotypic analysis (analysis of the Side Population -"SP" cells were combined with CD34, CD38, CD90 and CD133 expression analyses) to question the presence of primitive HSC in steady state blood of healthy humans.
Material and methods

Recovery of leukocytes and MNC from the LRF
The blood for transfusion purposes is collected only from the voluntary healthy blood donors. The cells were recovered from filters (T2975, Fresenius Kabi, Louviers, France) by counterflow elution as described (Ivanovic et al., 2006a (Ivanovic et al., , 2006b . The cells were then centrifuged at low gravity (10 min at 20°C, 320 g; Heraeus Multifuge S3, Yutz, France) to reduce the platelets contamination of the buffy coat. The platelet rich supernatants were discarded and the buffy coats containing residual RBC recovered and loaded on Ficoll (Bicoll separating solution -Biochrom AG, Berlin, Germany). The MNC fraction was harvested after 20 min of centrifugation at 290g (Heraeus Multifuge S3, Heraeus Multifuge S3, Yutz, France), then washed and resuspended in buffer for the CD34 + isolation. The cells from myeloma patients were obtained by leukapheresis after the standard mobilization protocol (4 g/m 2 intravenous (iv) cyclophosphamide followed by subcutaneous filgrastim (Amgen, Neuilly sur Seine, France; 5 μg/kg/day) until all leukapheresis procedures were collected) (Boiron et al., 2006) . The lowest CD34 + cell incidence before starting leukapheresis procedures was 20/μl for the series of patients whose results were considered in this study.
Isolation of CD34
+ cells CD34 + cells from MNC fraction issued from LDFs were isolated by using Miltenyi's (Miltenyi Biotec, Paris, France) "indirect" immunomagnetic technique (human CD34 + progenitor cell isolation kit "Macs") (Ivanovic et al., 2006a (Ivanovic et al., , 2006b : two passages by using the LS columns (Vario Macs Device). This approach enabled, in spite of very low starting concentration of CD34 + cells, relatively good CD34 + purity (80-98%). CD34 + cells from myeloma patients after mobilization -"Mobilized CD34
+ cells" -were selected directly from leukapheresis products using Isolex 300i (Miltenyi Biotec, Paris, France) device (Ivanovic et al., 2006b ).
Detection of CFU-GM, BFU-E and CFU-Mix committed progenitors
Freshly isolated CD34 + cells (isolated from LRF or cord blood) and their progeny after culture were plated in methylcellulose cytokine-supplemented kits (Stem Alpha ID, Saint Clement les Places, France) and cultured for 14 days in 35 mm Petri dishes (NUNC, Roskilde, Denmark). The colonies (N 50 cells) were then counted (Ivanovic et al., 2006a (Ivanovic et al., , 2006b ).
Evaluation of ex vivo expansion capacity of LRF-recovered CD34 + cells
Freshly isolated CD34 + cells were seeded at 20 × 10 3 cells/ml, and cultured in 175 cm 2 flasks (NUNC, Roskilde, Denmark) during 7 days in liquid (serum-free medium Macopharma HP01) cultures supplemented by SCF, G-CSF and MGDF (100 ng/ml each), IL-3 (0.5 ng/ml) (Ivanovic et al., 2004) .
Total cell counting
The cells were counted using automatic cell counter (Cell Dyn 3000, Abbott, Rungis, France).
CD34 + cell detection and immunophenotypical analysis
The CD34 + cell concentrations/purities were detected following the recommendations of the International Society of Hematotherapy and Graft Engineering (Sutherland et al., 1996) as previously described (Ivanovic et al., 2006a (Ivanovic et al., , 2006b . Briefly, three-color fluorescence was used to detect viable CD45 + /CD34 + cells that were counted directly by a flow cytometer (FACS Calibur, Becton Dickinson, San Jose, CA) by using trucount microbeads (Beckton Dickinson, San Jose, CA). For phenotypic characterization of cultured cells, the following fluorescein-coupled monoclonal antibodies were used: anti-CD13 (PE), anti-CD33 (PE), anti-CD61 (FITC) (all from Beckton Dickinson, San Jose, CA) and anti-CD41 (PE) (Pharmingen, San Diego, CA).
Detection of stem cells by their in vivo repopulating capacity (SRC) ST-HSC As described previously , the animal experiments were performed in compliance with the French regulation (License No: 3306002). 200 × 10 3 CD34 + cells on Day-0, as well as their whole 20) were injected to irradiated (3.5Gy;
60 Co source -Gamatron, Siemens, France) 8-10 week-old NOD/Scid mice (central animal-keeping facility of Bordeaux Segalen University). In order to improve the graft efficiency by depleting NK cells, recipient mice were injected with the anti-CD122 antibody (produced in our laboratory using the TM-β1 hybridoma originating from Dr Tanaka laboratory (Tanaka et al., 1991) ) 24 h prior to the transplantation (100 μg/mice). After 6-7 weeks, the animals were sacrificed and their femoral mononuclear bone marrow cells isolated and analyzed by flow-cytometry (FACS Calibur; Becton Dickinson, San Jose, CA) for human CD45 (PC7-coupled anti-human antibody, Immunotech, Marseille, France), CD33 and CD19 (Beckton Dickinson, San Jose, CA). To avoid false positive results due to control isotype, we used the non-injected mice to establish the "positivity threshold" which was 0.5% both for CD45 and CD33 (Ivanovic et al., 2004 .
LT-HSC
Secondary recipient mice were conditioned as primary recipients. The bone marrow from both femurs of primary recipients was flushed out in 1 ml of medium. Apart a 65 μl aliquot that was used for cell counting and detection of human CD45
+ cells by flow-cytometry, the total cellular content from both femurs of each primary recipient was centrifuged, resuspended in 30 μl of RPMI and injected intrafemorally (Robert-Richard et al., 2006) to the secondary recipient NOD/Scid mice. The mice were sacrificed 6-7 weeks later and the same staining and flow cytometry analysis as the one for primary recipients were performed on the bone marrow cells of injected femurs.
Analysis of "Side Population" (SP)
Hoechst low/negative cells, corresponding to cells that massively exclude the stain, have been designated SP cells by virtue of their typical flow cytometric profile in Hoechst red vs. Hoechst blue (Challen and Little, 2006; Johnnidis and Camargo, 2008) . In this cell population HSCs are highly enriched (Goodell, 2002; Lin and Goodell, 2006; Kim et al., 2002) . More recently, the same procedure based on the use of a different dye termed DCV (Dye Cycle Violet -DCV) was described (Telford et al., 2007) . DCV allows the delineation of SP cells displaying the same phenotypic and functional characteristics as those evidenced with Hoechst (Telford et al., 2007; She et al., 2008; Mathew et al., 2009) . Moreover it presents the advantage to be analyzed with a UV (350 nm) laser or violet (405 nm) laser whereas Hoechst strictly requires the UV one. The optimal conditions for our experimental set-up were fixed in the preliminary experiments aimed to establish (i) dose of VDC, (ii) FACS acquisition settings that depend on the laser used (UV 350 nm or near UV 375 nm (for Hoechst and VDC) and violet 405 nm (for VDC only)), (iii) the type of flow cytometer, and (iv) the configuration of filters. The incubation time of 120 min for human cells was explicitly stated in the publication on the web site "Goodell lab's protocols", (http://www.ucl.ac.uk/ich/ services/labservices/FCCF/protocols/goodell_hoechst_sp; see "other species" section).
In our hands, with this cell type and with our FACS configuration, 5 μM of VDC was found to be the optimal dose that gave rise to reproducible data. Freshly isolated or cultured steady state PB CD34 + cells (5 × 10 5 cells) were centrifuged for 10 min at 300 g in washing buffer (HBSS, 2% FCS, 10 mM Hepes) and resuspended at 10 6 cells/ml in reaction medium (DMEM, 2% FCS, 10 mM Hepes and 5 μM DCV). Cells were incubated with DCV 120 min at 37°C in a water bath. As control condition, an aliquot of cells is incubated in presence of 30 μM of Verapamil in order to block the ABC transporters and thus abrogate the dye efflux. The gate for SP was chosen according to Verapamil control included for each condition of each experiment.
At the end of the incubation, cells were washed in cold washing buffer for 10 min at 300g, resuspended in 100 μl of washing buffer for further membrane labeling with CD34-APCalexa750, CD38-PC7, CD90-APC or CD133-APC. In each sample, 20 μl of 7-AAD (viability dye) was added. Cells were incubated on ice for 20 min, then washed in washing buffer, and resuspended in the same buffer for flow cytometry analysis. The particular phenotypic subsets of SP cells in which HSCs were shown to be enriched in bone marrow and cord blood CD34 + cell population, based on CD38 (Beckman Coulter), CD133 (Miltenyi Biotech) and CD90 (BD Pharmingen) expression were evaluated by a multi-color analysis.
Results
Colony forming efficiency of steady state PB CD34 + cells recovered from the LRF The colony forming efficiency (frequency of committed progenitors) of steady state PB CD34 + cells is similar to the one of cord blood CD34 + cells (N = 10) and significantly higher than that of mobilized CD34 + cells (N = 19) (cumulative data from our research group obtained using the same culture system) ( Fig. 1A and Ivanovic et al., 2006a) .
Ex vivo expansion potential of steady state PB CD34 + cells isolated from LRFs
In serum free cultures supplemented with a cocktail of cytokines used for ex vivo expansion of CD34 + cells mobilized in peripheral blood (Ivanovic et al., 2006a) , the mean amplification factor was 25.3 fold, 14.1 fold and 12.5 fold for total cells, CD34 + cells, and CFU, respectively (Fig. 1B) .
Immunophenotype of cells expanded ex vivo from steady state PB CD34 + cells (Fig. 1C) confirms the capacity of these cells to generate cells of myeloid (CD13 and CD33) and megakaryocytic (CD41, CD61) lineage (Ivanovic et al., 2006a (Ivanovic et al., , 2006b , similar to cord blood CD34 + cells ) and CD34 + cells mobilized into peripheral blood (Ivanovic et al., 2006a ). An important fraction of cells remained CD34 positive at Day-7 (40%).
Immunophenotypic characterization of SP CD34 + cells isolated from LRFs and their ex vivo expansion progeny
The flow cytometry analysis of freshly isolated steady state PB CD34 + cells (Day-0) revealed the presence of SP cells in a low frequency (0.5 ± 0.2%) which persists (0.5 ± 0.1%) after ex vivo culture (Day-7) (overall population analyzed) (Fig. 2A) . The character of SP population was confirmed by its disappearance after inhibition of Ca-channels by Verapamil (Fig. 2B) . When only remaining CD34 + cells were analyzed after culture, the SP frequency was 0.7 ± 0.2% (Fig. 3A) . While on Day-0 all SP cells were CD34 + , on Day-7 some SP cells were identified as CD34 − (Fig. 3B) −/low population positive for CD90 on Day-0 (21.9 ± 3.1%) decreased on Day-7 (13,8 ± 4.5%) (Fig. 3D) , their percentage positive for CD133 (15% on Day-0) increased after culture (39.2 + 5.5% on Day-7) (Fig. 3E) .
In terms of absolute cell number, the total SP CD34 + population was amplified 21 fold after culture. The amplification of SP cells expressing the phenotypes considered as "primitive" was 10, 28 and 5.9 fold for SP CD34 + CD38 −/low , SP CD34 + CD38
−/low CD90 + and SP CD34 + CD38 −/low CD133 + cell population, respectively (Fig. 3F) . Bivariate plots concerning the quadrant settings delimiting CD38 vs. CD34 subsets in viable cells of isotype control labeled cells are provided in Supplementary Fig. 1 .
HSC with short-term repopulation potential in CD34
+ steady state PB cell population
Application of the same cell dose as the one used for CD34 + cells mobilized in peripheral blood did not result in engraftment of native NOD/Scid mice with steady state PB CD34 + cells. However, the treatment of mice with the anti-CD122 antibody improved the engrafting efficiency: injection of 2 × 10 5 freshly isolated steady state PB CD34 + cells into anti-CD122-treated NOD/Scid mice resulted in low engraftment rate: the mean human CD45 + chimerism was 0.8%. This cell dose yielded both "positive" and "negative" mice (0.5% threshold) with a maximum CD45 chimerism of 1.1% (Fig. 4A-i) . Similar engraftment rate was obtained for human CD33 (Fig. 4A-ii) marker. A 24 h culture did not improve this low engraftment capacity. Interestingly, cells that were expanded from the same number (2 × 10 5 ) of seeded steady state PB CD34 + cells during 7 days led to human hematopoietic engraftment of all mice (Figs. 4A-i,ii) . Furthermore, about 8 fold (6.3% vs. 0.8%) higher human CD45 (Fig. 4A-i (N = 19) ; the data represent means ± SEM. B. Day-7 expansion fold of total, CD34+ cells and CFU (Plating efficiency after culture was 207 CFU/1000 cells (440 CFU/1000 CD34+ cells)). The liquid cultures (7 days) (N = 13; each culture was initiated by CD34+ cell content of 1 LRF) composed of HP01 medium supplemented with SCF, G-CSF and MGDF (100 ng/ml each), IL-3 (0.5 ng/ml); the data represent mean ± SEM. C. Expression of CD34, CD13, CD33, CD41 and CD61 on cells expanded in cultures described in (B). The data represent mean ± SD. human cells engrafted in primary recipients to engraft secondary NOD/Scid recipient mice. These experiments were performed only with the cultured cells since the enhanced ST-HSC activity by ex vivo culture pointed to their potential interest for cell therapy. Thus, as expected, injection of Day-7 culture progeny of 1 × 10 6 steady state CD34 + cells resulted 6 to 7 weeks later in high human chimerism in primary recipients for the tested markers (Figs. 4B-i,ii) . When the bone marrow cells of primary recipients were injected in femur of secondary recipient, human hematopoietic chimerism was clearly detectable in 8/10 of mice 6 to 7 weeks after injection, (Figs. 4B-i,ii) . These results indicate that the very primitive stem cells (LT-HSC) are present among steady state blood CD34 + cells.
Discussion
The presence in the graft products of HSC exhibiting capacity of life-long hematopoietic reconstitution is mandatory for clinical transplantation. The secondary engraftment of immunodeficient mice by human hematopoietic cells issued from primary xenografted mice is presently the "gold standard" for testing LT-HSC. Recently, we successfully employed this method to test the graft potential of cord blood steady state as well as ex vivo amplified cells . These data are very likely to be relevant for engraftment in humans, taking into account that the maintenance of LT-HSC xenograft capacity after the ex vivo expansion of cord blood CD34 + cells is consistent with the ability of a graft to provide the long-term hematopoietic reconstitution of transplanted patients (Milpied et al., 2011) .
The results of this study clearly demonstrate the presence of very primitive HSCs (LT-HSC) in steady state blood CD34 + cells which were not lost in course of the ex vivo culture. This experimental evidence that LT-HSCs are present in human blood in steady state is in line with recent findings of Utter et al. (2008) of persisting microchimerism of donor type in war veterans who received transfusion(s) of non-leukodepleted blood several decades ago.
Concerning the ST-HSC, our results, demonstrating a low ability to engraft primary recipients of SRC on Day-0 and Day-1, are in line with those of Hirayama et al. (2003) who found similar proportion of engrafted mice and chimerism with steady state CD34 + cells after 4 h of incubation at 37°C.
Our results that reveal the presence of LT-HSC in steady state PB can provide the "missing piece of the puzzle" showing that all stages of hematopoietic stem cells circulate in steady state blood of healthy persons. Furthermore, all these cells, trapped together on LRFs, could be easily eluted for use (Ivanovic et al., 2006a (Ivanovic et al., , 2006b Peytour et al., 2010) . This could be of a great practical importance, since the leukoreduction, frequently applied and even mandatory in some countries (France, for example), produces a huge quantity of cell-saturated filters, which are actually destroyed as a medical waste. If one takes into consideration the real possibility to cryopreserve the cells issued from several filters of the same donor collected during a long period (several donations per year), the potential clinical value of these steady state PB cells becomes self-evident. The major interest in this source of HSC is further strengthened both by the fact that the ex vivo expansion of the hematopoietic stem and progenitor cells from CD34 + cells is proving its clinical utility (Reiffers et al., 1999; Boiron et al., 2006; Milpied et al., 2011) , and our data that show dramatic improvement of the HSC engraftment capacity of these steady state PB CD34 + cells by the ex vivo culture. The 8 fold enhancement of ST-HSC activity after 7 days of culture could result either from numerical amplification of SRC during the expansion culture or/and from an improvement of their homing/seeding in recipient's bone marrow niches, which remains to be elucidated in further studies. It is important to mention that this enhancement in HSC activity in the course of culture is paralleled by the 12.5 fold amplification of committed progenitors (14 fold of CD34 + cells). Indeed, the committed progenitor content in an ex vivo expanded hematopoietic graft appears to be a determining factor for the shortening of neutropenia period and related infectious risks after hematopoietic transplantation in patients (Milpied et al., 2011; Utter et al., 2008; Reiffers et al., 1999; Boiron et al., 2006) .
The expression of chemokines, adhesive molecules, cytokine receptors and other markers was extensively studied on PB steady state CD34 + cells (Lataillade et al., 2005) . However, one cannot assume that the expression of these molecules at the surface of the total CD34 + cell population is strictly relevant to stem cells, especially after the ex vivo culture (Danet et al., 2001) , since CD34 + cell population is functionally heterogeneous and contains a minority of the stem cells. Furthermore, primitive stem cells are identified on the basis of their capacity to repopulate secondary recipients (thus indirectly) and remain phenotypically "elusive" due to their very low frequency and the fact that the known immunophenotype markers do not seem to be specifically related to the stem cell potential and function. Nevertheless, HSCs are enriched in some phenotypically-defined CD34 cell subsets and in "Side Population" (Telford et al., 2007) , defined initially on a very restrained subset of murine and human bone marrow and human cord blood cells on the basis of the activity of a membrane calcium-dependent pump ("ABC transporters") capable to reject some molecules from the cell (Kim et al., 2002) . We present here the first data demonstrating that such a population of cells exists in the steady state human blood and is numerically enhanced after the ex vivo culture (Fig. 3F) . We detected the SP frequency 0.5% to 0.7% which is consistent with the data published for the CD34 + (CD34 + 38 − ) populations originating from: peripheral blood after mobilization (Josefsen et al., 2011) human fetal and adult liver (Uchida et al., 2001; Pierre-Louis et al., 2009 ) and other tissues (Asakura and Rudnicki, 2002) .
These findings are consistent with a low SRC activity which is increased after ex vivo culture (Fig. 4A) . In a parallel project, we found that CD34 + CD38 −/low and not CD34 + CD38 + fraction of cultured steady state PB cells contains the cells exhibiting the capacity to engraft NSG mice (giving human CD45 + , CD33 + (myeloid) and CD19 + (lymphoid) cells in murine bone marrow) (work in progress). Thus, the SP cells were analyzed with respect to CD38 expression (Figs. 3B, C) . Taking into account only CD34 + CD38 −/low SP cells, the phenomenon of increase in absolute cell number after culture persists (10 fold) (Fig. 3F) , which is similar to the increase in SRC activity in the same condition (human chimerism increased about 8 fold), suggesting that the HSCs are really highly enriched in this SP CD34 + CD38 −/low cell fraction. In line with this observation are We can thus conclude that the CD34 + cells purified from LRF steady state PB contain a restricted population of short-and long-term repopulating HSC, a finding completely consistent with the one of a low-frequency SP and SP CD34 + CD38 −/low populations (as well as its CD90 + and CD133 + subpopulations). These populations increase after culture as does the SRC activity.
We envision that these results should encourage new R&D projects devoted to the therapeutic use of steady state PB cells issued from LRF as a source of autologous or allogeneic HSC to be expanded before their reinjection to patients.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.scr.2013.04.003.
